Gill A, Hoogwerf B, Burger J, Bruce S, MacConell L, Yan P, Braun D, Giaconia J, Malone J: Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
Accurate peptide calculator results in seconds
Michael Palladinetti, global head of business development and licensing at Sanofi, told delegates attending Bio Europe Spring in Barcelona, Spain last week that history has shown us time and time again that no one has the monopoly on the next wave of innovation. Citing the recent GLP-1 wave, Palladinetti said the industry has a bit of fear of missing out (FOMO) and paid kudos to Lily and Novo for staying in the space. He added how innovation is also very difficult and that industry players need to have a broad view. Both firms are pioneers in the diabetes space, having launched their own versions of insulin over 100 years ago
Yet, this study suffers of a limited sample size
Retatrutide is an investigational triple agonist that simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
HRT Supports Reduced Visceral Fat Accumulation: Estrogen therapy helps maintain the subcutaneous fat distribution pattern of younger women, reducing dangerous visceral fat deposits around organs